Our study unveiled molecular mechanisms underlying GC metastasis driven by RASA1 mutations and Nf2 deficiency and proposed a novel therapeutic strategy involving combined inhibition of Bcl-2 family members and YAP for treatment of highly metastatic GC. This evidence concerns the gene BCL2 and gastric cancer.